Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UTILITI: Altuviiio for Immune Tolerance Induction in Hemophilia A
NCT07158606Phase 4Not yet recruiting
- Sponsor
- Versiti
- Start
- Dec 2026
- Primary completion
- Dec 2031
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 4 trial of efanesoctocog alfa in hemophilia A, sponsored by Versiti. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
efanesoctocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT07158606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07158606.